Cargando…

Biology and Targetability of the Extended Spectrum of PIK3CA Mutations Detected in Breast Carcinoma

PURPOSE: Alpelisib is a PI3K alpha (PI3Kα)-selective inhibitor approved for the treatment of hormone receptor–positive/HER2-negative (HR(+)/HER2(−)) PIK3CA-mutated advanced breast cancer (ABC) based on the SOLAR-1 trial, which defined 11 substitutions in exons 7, 9, and 20 in PIK3CA (SOLAR1m). We re...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rugo, Hope S., Raskina, Kira, Schrock, Alexa B., Madison, Russell W., Graf, Ryon P., Sokol, Ethan S., Sivakumar, Smruthy, Lee, Jessica K., Fisher, Virginia, Oxnard, Geoffrey R., Tukachinsky, Hanna
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Association for Cancer Research 2023
Materias:	Precision Medicine and Imaging
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10011882/ https://www.ncbi.nlm.nih.gov/pubmed/36321996 http://dx.doi.org/10.1158/1078-0432.CCR-22-2115

Ejemplares similares

The Pan-Tumor Landscape of Targetable Kinase Fusions in Circulating Tumor DNA
por: Lee, Jessica K., et al.
Publicado: (2022)

Genetic Heterogeneity and Tissue-specific Patterns of Tumors with Multiple PIK3CA Mutations
por: Sivakumar, Smruthy, et al.
Publicado: (2023)

Multiple PIK3CA mutation clonality correlates with outcomes in taselisib + fulvestrant-treated ER+/HER2–, PIK3CA-mutated breast cancers
por: Hutchinson, Katherine E., et al.
Publicado: (2023)

Real-world Validation of TMB and Microsatellite Instability as Predictive Biomarkers of Immune Checkpoint Inhibitor Effectiveness in Advanced Gastroesophageal Cancer
por: Graf, Ryon P., et al.
Publicado: (2022)

Genomic Biomarkers and Genome-Wide Loss-of-Heterozygosity Scores in Metastatic Prostate Cancer Following Progression on Androgen-Targeting Therapies
por: Zurita, Amado J., et al.
Publicado: (2022)

Unique Spectrum of Activating BRAF Alterations in Prostate Cancer
por: Chehrazi-Raffle, Alex, et al.
Publicado: (2023)

Clinical and pathological features associated with circulating tumor DNA content in real‐world patients with metastatic prostate cancer
por: Antonarakis, Emmanuel S., et al.
Publicado: (2022)

Comprehensive pan-cancer genomic landscape of KRAS altered cancers and real-world outcomes in solid tumors
por: Lee, Jessica K., et al.
Publicado: (2022)

Comparative Effectiveness of Immune Checkpoint Inhibitors vs Chemotherapy by Tumor Mutational Burden in Metastatic Castration-Resistant Prostate Cancer
por: Graf, Ryon P., et al.
Publicado: (2022)

Response of Brain Metastases From PIK3CA-Mutant Breast Cancer to Alpelisib
por: Batalini, Felipe, et al.
Publicado: (2020)

Detection of an ALK Fusion in Colorectal Carcinoma by Hybrid Capture‐Based Assay of Circulating Tumor DNA
por: Lai, Andrea Z., et al.
Publicado: (2017)

Circulating Tumor DNA Monitoring on Chemo-immunotherapy for Risk Stratification in Advanced Non–Small Cell Lung Cancer
por: Pellini, Bruna, et al.
Publicado: (2023)

Tissue and liquid biopsy profiling reveal convergent tumor evolution and therapy evasion in breast cancer
por: Sivakumar, Smruthy, et al.
Publicado: (2022)

BRAF V600E and RNF43 Co-mutations Predict Patient Outcomes with Targeted Therapies in Real-World Cases of Colorectal Cancer
por: Quintanilha, Julia C F, et al.
Publicado: (2023)

4108 Artificial Intelligence-Based Quantification of the General Movement Assessment Using Center of Pressure Patterns in Healthy Infants
por: Johnson, Tara Lynn, et al.
Publicado: (2020)

Prognostic Significance of Blood-Based Multi-cancer Detection in Plasma Cell-Free DNA
por: Chen, Xiaoji, et al.
Publicado: (2021)

Pan-cancer Analysis of Homologous Recombination Repair–associated Gene Alterations and Genome-wide Loss-of-Heterozygosity Score
por: Westphalen, C. Benedikt, et al.
Publicado: (2022)

Durable responders in advanced NSCLC with elevated TMB and treated with 1L immune checkpoint inhibitor: a real-world outcomes analysis
por: Huang, Richard S P, et al.
Publicado: (2023)

Determinants of Response to Talazoparib in Patients with HER2-Negative, Germline BRCA1/2-Mutated Breast Cancer
por: Blum, Joanne L., et al.
Publicado: (2022)

Comparison of PIK3CA Mutation Prevalence in Breast Cancer Across Predicted Ancestry Populations
por: Chen, Jessica W., et al.
Publicado: (2022)

PIK3CA mutation status, progression and survival in advanced HR + /HER2- breast cancer: a meta-analysis of published clinical trials
por: Fillbrunn, Mirko, et al.
Publicado: (2022)

Triple-Negative PAM50 Non-Basal Breast Cancer Subtype Predicts Benefit from Extended Adjuvant Capecitabine
por: Asleh, Karama, et al.
Publicado: (2023)

Circulating Tumor DNA Analysis in Advanced Urothelial Carcinoma: Insights from Biological Analysis and Extended Clinical Follow-up
por: Lindskrog, Sia V., et al.
Publicado: (2023)

Diagnostic Performance of a Tumor Marker Gene Test to Personalize Serum CA19–9 Reference Ranges
por: Dbouk, Mohamad, et al.
Publicado: (2023)

Carcinogenesis of PIK3CA
por: German, Sidra, et al.
Publicado: (2013)

APOBEC Mutational Signatures in Hormone Receptor–Positive Human Epidermal Growth Factor Receptor 2–Negative Breast Cancers Are Associated With Poor Outcomes on CDK4/6 Inhibitors and Endocrine Therapy
por: Sammons, Sarah, et al.
Publicado: (2022)

Homologous Recombination Deficiency Landscape of Breast Cancers and Real-World Effectiveness of Poly ADP-Ribose Polymerase Inhibitors in Patients With Somatic BRCA1/2, Germline PALB2, or Homologous Recombination Deficiency Signature
por: Batalini, Felipe, et al.
Publicado: (2023)

Tumor Mutational Burden in Real-World Patients With Pancreatic Cancer: Genomic Alterations and Predictive Value for Immune Checkpoint Inhibitor Effectiveness
por: Quintanilha, Julia C.F., et al.
Publicado: (2023)

Tumor Fraction Correlates With Detection of Actionable Variants Across > 23,000 Circulating Tumor DNA Samples
por: Husain, Hatim, et al.
Publicado: (2022)

Effectiveness of Alpelisib + Fulvestrant Compared with Real‐World Standard Treatment Among Patients with HR+, HER2–, PIK3CA‐Mutated Breast Cancer
por: Turner, Stuart, et al.
Publicado: (2021)

PIK3CA in Colorectal Cancer
por: Cathomas, Gieri
Publicado: (2014)

4429 Powering precision medicine research with the efficient construction of large diverse cohorts
por: Petukhova, Lynn, et al.
Publicado: (2020)

4058 Enhanced efficiency of large-scale clinical proteomic studies: when less is more
por: Thomas, Stefani, et al.
Publicado: (2020)

4199 A pilot randomized controlled trial of precision care for smoking cessation in the Southern Community Cohort Study
por: Senft, Nicole, et al.
Publicado: (2020)

4513 European Ancestry as a Risk Factor for Atrial Fibrillation in Puerto Rican Hispanics
por: Gonzalez-Cordero, Ariel
Publicado: (2020)

4440 Enhanced radiation therapy using chlorin-e6 conjugated gold nanoparticles
por: Jenkins, Samir V, et al.
Publicado: (2020)

4089 Clinical Implementation of Monte Carlo Dose Calculation for Patient-Specific Radiotherapy Quality Assurance
por: Parenica, Holly Marie, et al.
Publicado: (2020)

4228 A latent class analysis of seriously ill adults with multiple chronic conditions receiving palliative care
por: Murali, Komal, et al.
Publicado: (2020)

4292 Epigenetic Age and Depressive Symptoms in African American Women with Cardiometabolic Conditions
por: Perez, Nicole B, et al.
Publicado: (2020)

4167 Peri-transplant Lung Microbiome Reveal Oral Bacteria, Pepsin And Inflammatory Markers Co-associate With Primary Graft Dysfunction, Implicating Aspiration As A Potential Contributor
por: McGinniss, John Evan, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_c50d1f6hv0todvnnvubi34kq7v